IC
TRDA icon

Inscription Capital’s Entrada Therapeutics TRDA Stock Holding History

Inscription Capital’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$176K Buy
23,941
+12,106
+102% +$116K 0.02% 726
2026
Q1 		$149K Hold
11,835
– – 0.02% 646
2025
Q4 		$122K Hold
11,835
– – 0.01% 643
2025
Q3 		$68.6K Buy
+11,835
New +$69.2K 0.01% 626

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Inscription Capital's TRDA Position: Q2 2026 in Review

Inscription Capital increased its Entrada Therapeutics (TRDA) stake by 102% in Q2 2026, buying an estimated $116K and bringing the position to 23,941 shares worth $176K. The position accounts for 0.02% of the portfolio, ranked #726.

Inscription Capital first reported a position in TRDA in Q3 2025 and has held it in 4 quarters since. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Inscription Capital held 23,941 shares of Entrada Therapeutics worth $176K as of Q2 2026.
  • Inscription Capital bought 12,106 Entrada Therapeutics shares in Q2 2026, an estimated $116K.
  • Entrada Therapeutics made up 0.02% of Inscription Capital's portfolio in Q2 2026, its #726 holding.
  • Inscription Capital first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.